Pfizer's Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions
Pfizer's Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions
Pfizer Inc. (NYSE:PFE) has recently launched a multi-year cost reduction initiative aimed at saving approximately $1.5 billion by the end of 2027.
輝瑞公司（紐約證券交易所代碼：PFE）最近啓動了一項爲期多年的成本削減計劃，旨在到2027年底節省約15億美元。
This new program builds upon a $4 billion cost reduction plan announced last year.
這項新計劃建立在去年宣佈的40億美元成本削減計劃的基礎上。
The move came as the pharmaceutical giant faces declining investor interest and diminishing sales from its COVID-19 vaccine and treatments.
此舉是在這家制藥巨頭面臨投資者興趣下降以及其 COVID-19 疫苗和治療的銷售減少之際採取的。
Also Read: Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
另請閱讀：專家預測 COVID-19 病例將增加：疫苗庫存攀升
What Happened?
發生了什麼？
Pfizer's shares rose 2.6% to $29.30 following the announcement on Wednesday, but remain down about 24% over the past year and nearly half of their peak value from December 2021. As of Thursday trading, the stock was down -2.72% by 11:50 a.m. ET.
輝瑞股價在週三宣佈後上漲2.6％，至29.30美元，但在過去一年中仍下跌約24％，是自2021年12月以來峯值的近一半。截至週四的交易，截至美國東部時間上午11點50分，該股下跌了-2.72％。
The program will incur one-time charges of $1.7 billion, mainly for severance and implementation costs, with most charges expected this year. Actual cash outlays are anticipated in 2025 and 2026.
該計劃將產生17億美元的一次性費用，主要用於遣散費和實施費用，預計今年將收取大部分費用。實際現金支出預計將在2025年和2026年出現。
The initiative aims to enhance operational efficiencies, restructure its network, and improve its product portfolio. No job cuts have been announced yet, but further details will be shared in future earnings calls and investor events.
該計劃旨在提高運營效率，重組其網絡並改善其產品組合。尚未宣佈裁員，但將在未來的業績電話會議和投資者活動中分享更多細節。
Earlier this month, Pfizer raised its annual earnings forecast and reported a better-than-expected first-quarter profit, partly due to cost reductions. CFO David Denton highlighted the strong cost control across their manufacturing platform.
本月早些時候，輝瑞上調了年度收益預期，並公佈了好於預期的第一季度利潤，部分原因是成本降低。首席財務官戴維·丹頓強調了整個製造平台的強大成本控制。
Why It Matters
爲什麼重要
Pfizer's cost-cutting measures are crucial as the company grapples with reduced revenue from its COVID-19 treatments. The financial headwinds have put additional pressure on Pfizer to find new revenue streams and cut costs effectively.
輝瑞的削減成本措施至關重要，因爲該公司正在努力應對其 COVID-19 治療收入減少的問題。財務不利因素給輝瑞帶來了額外的壓力，要求他們尋找新的收入來源並有效削減成本。
The company surprised analysts with a profit earlier this year, largely driven by its efforts to revolutionize cancer treatment. Pfizer's focus on innovative cancer therapies could be its best chance to regain investor confidence.
該公司今年早些時候的盈利令分析師感到驚訝，這主要是由其徹底改變癌症治療的努力所推動的。輝瑞對創新癌症療法的關注可能是其恢復投資者信心的最佳機會。
PFE Stock Showing Strong Bullish Momentum
PFE 股票顯示出強勁的看漲勢頭
Currently, Pfizer's stock exhibits strong bullish momentum. Its share price is trading above its 5-, 20-, and 50-day exponential moving averages. This indicates buying pressure and positive future movement.
目前，輝瑞的股票表現出強勁的看漲勢頭。其股價交易價格高於其5、20和50天指數移動平均線。這表明買盤壓力和積極的未來走勢。
Chart: Benzinga Pro
圖表：Benzinga Pro
The share price is $28.87, while the 8-day simple moving average (SMA) stands at $28.79, the 20-day SMA at $27.90, and the 50-day SMA at $27.26, all suggesting a bullish outlook.
股價爲28.87美元，而8天簡單移動平均線（SMA）爲28.79美元，20天均線爲27.90美元，50天均線爲27.26美元，均表明前景看漲。
However, the 200-day SMA is $29.71, which presents a more cautious signal.
但是，200天均線爲29.71美元，這發出了更爲謹慎的信號。
Chart: Benzinga Pro
圖表：Benzinga Pro
The Moving Average Convergence Divergence (MACD) indicator at 0.61 also supports a bullish sentiment. The Relative Strength Index (RSI) of 61.08 indicates that the stock is heading towards the overbought zone at and beyond 70. The Bollinger Bands have the stock trading in the upper (bullish) band, suggesting a bullish trend.
0.61的移動平均收斂散度（MACD）指標也支持看漲情緒。相對強弱指數（RSI）爲61.08，表明該股正走向70及以上的超買區域。布林帶使股票交易處於上限（看漲）區間，這表明存在看漲趨勢。
Pfizer's recent cost reduction efforts and technical indicators suggest a strong bullish outlook for Pfizer stock in the near term. The ongoing strategic initiatives and expected savings could drive continued positive performance.
輝瑞最近的削減成本措施和技術指標表明，輝瑞股票在短期內前景強勁。正在進行的戰略舉措和預期的節省可能會推動持續的積極業績。
Investors should monitor upcoming earnings calls for further details on the cost-cutting measures and potential job cuts, which could impact the stock's trajectory.
投資者應關注即將舉行的業績電話會議，以獲取有關削減成本措施和潛在裁員的更多細節，這可能會影響該股的走勢。
Photo: Shutterstock
照片：Shutterstock
譯文內容由第三人軟體翻譯。